



Colby Pharmaceutical Company

CEO David Zarling PhD MBA

dzarling@colbypharmaceuticals.com

650-333-3150

March 2009


Colby Overview

- In-licensed drugs from WARF/UW-Madison Clinical Cancer Center
- Compelling data for proprietary drug candidates with known MOAs & unmet medical needs in prostate & other solid tumors with large markets
- Validated drugs through grants
- IND enabling data funded by NCI for 2 lead PCa drugs
 - IND data complete for CPC-100
 - IND data in progress for CPC-200 & complete in 2H2009
- Phase I/IIa trial of CPC-100 for post-ADT PCa, planned in 2009
- Phase I/IIa trial of CPC-200 for pre-ADT PCa, planning for 2010
- Pipeline CPC-300 & -410 signal transduction inhibitor drugs with compelling efficacy & safety in metastatic prostate, pancreas, brain & other solid tumors
- Phase I trial of CPC-410 for solid tumors, planning for 2011
- Veteran management, clinical leadership, strong IP



Management & Directors

David Zarling PhD, MBA	CEO & Board Director	Pangene, SRI International Pharma Drug Development
Bill Massey PhD	Acting Chief Operating Officer	Litmus Molecular Design, BWMC, Arctos, AstraZeneca, Quintiles, Astra Merck, Merck
Minesh Mehta MD	Chief Medical Officer	UWCCC (former Oncology Chair), TomoTherapy
Hirak Basu PhD	Chief Scientific Officer	UWCCC, Sill Biomedical, UCSF School of Pharmacy
Alex Zhavoronkov PhD	Business Development	GTCbio, Mediox, ATI Tech
Anne Vallerga PhD	VP Grants/Contracts & Board Director	Stanford University Medical School IRB
Ken Narducy PhD, MBA	Outside Board Director, Chairman	St Charles Pharma, Centaur, Oculex, Cooper, Schering- Plough, Abbott
Craig Heim MBA	Board Observer for WARF	WARF, Grace Matthews Investment Bank



Scientific Advisory Board

George
Wilding MD

Co-Chairman,
Director UWCCC

Prostate cancer expert;
CPC-100, CPC-200

Richard
Zare PhD


Co-Chairman,
Chair Stanford
Chemistry Dept.

Chemistry expert;
co-founding SAB
member of multiple
corporations

Hasan
Mukhtar PhD


UWCCC

Cancer drug expert;
CPC-300




CPC-100

- 1st-in-class therapeutic oral drug for androgen-dependent & -independent PCa, increases animal survival & time to tumor progression, decreases PSA
- Multiple molecular target signal transduction inhibitor mechanism of action
 - anti-inflammatory
 - anti-androgenic
 - oxidative stress-& immune-modulator
- Safe and versatile in animals
 - very low toxicity, no pro-estrogenic or other negative side-effects
 - administered orally or by injection
 - molecularly targeted therapy
 - IND-enabling data collection complete & clinical trial protocol finalized
- Straight-forward API and tablet formulation manufacturing



Summary Of CPC-100 Advantages Compared To SOC ADT Drugs


<u>Drug Activity</u>	<u>Bicalutamide</u>	<u>Flutamide</u>	<u>Nilutamide</u>	<u>CPC-100</u>
Androgen-Dependent PCa Rx	Yes	Yes	Yes	Yes
Pro-Estrogenic negative side-effects	Yes	Yes	Yes	No
Androgen-Independent PCa Rx	No	No	No	Yes



CPC-100 Development Status


All pre-clinical studies completed, including:

- ✓ CPC-100 drug efficacy data
- ✓ GMP active pharmaceutical ingredient
- ✓ GLP drug stability
- ✓ GLP analytical method
- ✓ GLP genotoxicity battery
- ✓ GLP rat toxicology
- ✓ GLP dog toxicology



CPC-200

- 1st-in-class therapeutic oral drug for PCa, increases time to tumor progression & survival, decreases PSA
- Single target signal transduction inhibitor mechanism of action
 - irreversible inhibitor oxidase enzyme; suicide substrate inhibits oxidase
 - substrate present in prostate at 500x other cells
 - inhibits production of hydrogen peroxide by specific oxidase inhibition
 - may also treat brain, colon & lung cancer, as well as prostate
- Safe and versatile
 - very low toxicity, no pro-estrogenic or other negative side-effects
 - oral administration, or may be implanted or injected
 - targeted therapy
 - IND-enabling data is >half complete & clinical protocol consensus
- Straight-forward manufacturing & formulation



CPC-200 Development Status

Completed

- ✓ GMP API
- ✓ Non-GLP mouse toxicology
- ✓ Analytical method
- ✓ Drug stability

Funded & In-Progress

- GLP oral formulation
- GLP genotoxicity battery
- GLP rat toxicology
- GLP dog toxicology



CPC-410

- Molecularly targeted mitochondria superoxide dismutase mimetic
- Spin trap with no effect on electron transport
- Safe at therapeutic doses in animals
- Oral or injectable & passes blood brain barrier
- Therapeutic for advanced therapy-resistant tumors, including:
 - radiation-resistant, hormone-resistant, chemo-resistant PCa
 - chemo-resistant GBM & other other chemo-resistant solid tumors



Summary

- Clinical development of signal transduction inhibitor drugs meeting unmet medical needs in large existing cancer markets
- Colby drugs more effective than SOC in animal models
- Oral formulations
- 3 drug candidates for entry into clinical trials, 1 each in 2009, 2010 & 2011
- Pipeline drug efficacy in metastatic therapy-resistant prostate, brain & other solid tumors; partnering and out-licensing revenues
- Patients more likely to be scripted, reimbursed, remain on potent orally available & safe therapeutic drug
- Veteran management, clinical leadership, strong IP

